Showing 1 - 4 results of 4 for search 'Geoffrey L Uy', query time: 0.03s Refine Results
  1. 1
    Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

    Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors by Michael G. Martin, John F. DiPersio, Geoffrey L. Uy

    Published 2011-12-01
    Get full text
    Article
  2. 2
    Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

    Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML by Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet

    Published 2021-07-01
    Get full text
    Article
  3. 3
    Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

    Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice. by Lukas D Wartman, John S Welch, Geoffrey L Uy, Jeffery M Klco, Tamara Lamprecht, Nobish Varghese, Rakesh Nagarajan, Timothy J Ley

    Published 2012-01-01
    Get full text
    Article
  4. 4
    P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

    P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA by Joshua D. Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Nalina Dronamraju, Stefan Faderl, Tara L. Lin, Geoffrey L. Uy, Jeffrey Lancet, Jorge Cortes

    Published 2023-08-01
    Get full text
    Article

Search Tools: